GP(33-41) TFA

Cat. No.: HY-P0323A

Molecular Formula: $C_{48}H_{70}F_3N_{11}O_{15}S$

Molecular Weight: 1130.19

Target: Arenavirus

Pathway: Anti-infection

Storage: Sealed storage, away from moisture and light
Powder -80°C 2 years
-20°C 1 year
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 1.82 mg/mL (1.61 mM; ultrasonic and adjust pH to 4 with HCl)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.8848 mL	4.4240 mL	8.8481 mL
	5 mM	---	---	---
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC_{50} of 344 nM[1].

In Vitro

GP(33-41) TFA sensitizes MC57 and T2-D^b cells to lysis with ED_{50}s of 0.9±0.6 and 2.5±0.7 nM[1].
The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.

[2]. Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37(3):798-806.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA